Breaking News, Collaborations & Alliances

I-Mab Biopharma Joins Forces with MorphoSys

Deal centers on MorphoSys’s MOR202 investigational cancer therapy

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

I-Mab Biopharma and MorphoSys AG have entered into an exclusive regional licensing agreement to develop and commercialize MOR202 in China, Taiwan, Hong Kong and Macao. MOR202 is MorphoSys’s proprietary investigational antibody against CD38, for which recruitment of a European Phase 1/2a clinical study in relapsed/refractory multiple myeloma has been concluded. I-Mab will assume exclusive responsibility for all subsequent development and commercialization of MOR202 in the agreed territor...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters